Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome
|
|
- Raymond Robertson
- 6 years ago
- Views:
Transcription
1 REVIEW Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Han-Mou Tsai, MD imah Hematology Associates, New Hyde Park, NY. ABSTRACT Patients presenting with microangiopathic hemolysis and thrombocytopenia are often given the diagnosis of thrombotic thrombocytopenic purpura and treated with plasma exchange until the acute episode is over. Recent findings have shown that acquired thrombotic thrombocytopenic purpura is a chronic autoimmune disease with inhibitory antibodies of a disintegrin and metalloprotease with thrombospondin repeat, member 13 and are at risk of relapses that may be preventable. Furthermore, many of the patients given the diagnosis of thrombotic thrombocytopenic purpura really have atypical hemolytic uremic syndrome due to defective complement regulation that can be more effectively treated to prevent death and end-stage renal failure with eculizumab, a humanized monoclonal antibody of complement C5. These advances indicate that an accurate differential diagnosis of microangiopathic hemolysis is essential for optimal patient management Elsevier Inc. All rights reserved. The American Journal of Medicine (2013) 126, KEYWORDS: ADAMTS13; Atypical hemolytic uremic syndrome; Complement regulation; Microangiopathic hemolytic anemia; Thrombotic thrombocytopenic purpura First recognized in the 1970s as a disorder distinct from thrombotic thrombocytopenic purpura and the typical shiga toxin associated hemolytic uremic syndrome, atypical hemolytic uremic syndrome refers to the constellation of acute renal failure, thrombocytopenia, and microangiopathic hemolysis without antecedent shiga toxin induced hemorrhagic diarrhea. Subsequent studies show that atypical hemolytic uremic syndrome also occurs sporadically and affects adults. The severity of renal failure is variable, ranging from severe, irreversible renal failure to mild reversible azotemia. Because of its overlap with thrombotic thrombocytopenic purpura in the features of microangiopathic hemolytic anemia and thrombocytopenia, atypical hemolytic uremic Funding: Some of the author s works discussed in the article were supported by Grant R01 HL62136 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. Conflict of Interest: The sole author has been a speaker and a member of the advisory boards of Alexion, Inc, but did not receive support for his research work or preparing this manuscript. Authorship: The author is solely responsible for the content of this manuscript. Requests for reprints should be addressed to Han-Mou Tsai, MD, imah Hematology, 105 Robby Lane, New Hyde Park, NY address: hmtsai@gmail.com syndrome has often been considered merely a variant of thrombotic thrombocytopenic purpura. Consequently, the diagnosis of atypical hemolytic uremic syndrome is unrecognized or viewed as a form of thrombotic thrombocytopenic purpura, and treated as such with plasma exchange. Without a pathogenetic basis, the original view of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome as 2 distinct disorders fell to disfavor and has been held only by a minority of physicians. Advances in the last 15 years have shown that thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome not only differ in pathogenesis but also require different management. The similarity between the 2 disorders in causing thrombocytopenia and microangiopathic hemolysis is an epiphenomenon of microvascular thrombosis. With eculizumab newly approved for the treatment of atypical hemolytic uremic syndrome, it is more critical than ever to distinguish the disease from thrombotic thrombocytopenic purpura. PATHOGENESIS OF MICROANGIOPATHIC HEMOLYSIS Fragmentation of the red blood cells occurs in 2 types of clinical conditions that share the common feature of abnor /$ -see front matter 2013 Elsevier Inc. All rights reserved.
2 Tsai Untying the Atypical Hemolytic Uremic Syndrome Knot 201 mal intravascular shear stress: vascular devices, such as prosthetic heart valves, ventricular assist devices and extracorporeal oxygenators; and microvascular stenosis (Figure 1). In the absence of vascular devices, fragmentation of the red blood cells signifies stenosis in the arterioles and capillaries. At least 5 different types of arteriolar stenosis are observed to be associated pathologically with microangiopathic hemolysis (Table 1): (1) von Willebrand factor platelet thrombosis, as typically observed in patients with thrombotic thrombocytopenic purpura (Figure 2A-D); (2) platelet-fibrin thrombosis, as exemplified in patients with disseminated intravascular coagulopathy; (3) tumor cell invasion of the microvasculature in patients with metastatic neoplasm; (4) microvascular vasculitis complicating autoimmune disorders such as systemic lupus erythematosus or certain infections such as Rocky Mountain spotted fever; and (5) thrombotic microangiopathy, as observed in patients with shiga toxin associated hemolytic uremic syndrome CLINICAL SIGNIFICANCE or atypical hemolytic uremic syndrome (Figure 2E-H). In thrombotic microangiopathy, endothelial changes such as endothelial cell swelling or disruption, accompanied with intimal expansion and cellular proliferation, are prominent. With or without thrombosis, these changes may cause microvascular stenosis or occlusion. In addition, abnormal vascular permeability may cause interstitial edema of the Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome are major disorders causing microangiopathic hemolysis in patients without vascular devices or other diseases. Severe ADAMTS13 deficiency defines the diagnosis of thrombotic thrombocytopenic purpura, which is treated with plasma exchange or infusion and rituximab. Advanced renal failure, hypertension, or abnormal vascular permeability favor atypical hemolytic uremic syndrome due to complement dysregulation, which is treated with eculizumab. brain and other organs, as well as fluid accumulation in cavitary spaces, contributing to organ dysfunction in patients with thrombotic microangiopathy. In contrast, in thrombotic thrombocytopenic purpura, organ dysfunction results primarily from ischemia; the endothelium and vessel wall structures are intact, and no abnormal permeability or inflammatory cell infiltration is evident. It has been a common practice to equate the clinical constellation of thrombocytopenia and microangiopathic hemolysis with thrombotic microangiopathy (TMA); and the syndrome of thrombocytopenia, microangiopathic hemolysis and renal failure with thrombotic thrombocytopenic purpura (TTP) or thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome (TTP/HUS). Either practice obscures the important difference among the various causes of microangiopathic hemolysis. Two types of molecular mechanisms have been identified to cause idiopathic microangiopathic hemolysis: 1-6 Defective regulation of von Willebrand factor activity due to deficiency in a disintegrin and metalloprotease with thrombospondin repeat, member 13 (ADAMTS13), causing von Willebrand factor platelet aggregation in thrombotic thrombocytopenic purpura; and Defective regulation of the complement system due to mutations or autoantibodies of complement activators or regulators, causing thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome. Whereas ADAMTS13 deficiency is the only known cause of von Willebrand factor platelet thrombosis in thrombotic thrombocytopenic purpura, thrombotic microangiopathy is not specific for defective complement regulation because it may result from other causes of endothelial injury. Figure 1 Pathogenesis of microangiopathic hemolytic anemia. Abnormally high levels of shear stress, created by vascular devices (eg, left ventricular assist device, extracorporeal membrane oxygenator, or prosthetic heart valves) or arteriolar stenosis, may lead to fragmentation of the red blood cells. In the absence of vascular devices, microangiopathic hemolysis signifies arteriolar stenosis, which is accompanied by thrombocytopenia if the stenosis is due to thrombosis. RBC red blood cell. VON WILLEBRAND FACTOR, ADAMTS13, AND THROMBOTIC THROMBOCYTOPENIC PURPURA von Willebrand factor is a glycoprotein secreted from endothelial cells as a large polymeric form but exists in normal plasma as a series of multimers with progressively smaller sizes. The primary function of von Willebrand factor is to support platelet adhesion at sites of microvascular injury, where it binds to type VI collagen and other components of the exposed vessel wall, becoming rapidly unfolded and activated by the high levels of shear stress at the blood-vessel wall boundary, thereby providing the substrate to support platelet adhesion and aggregation. Thanks to its responsiveness to shear stress, von Willebrand
3 202 The American Journal of Medicine, Vol 126, No 3, March 2013 Table 1 Different Types of Microvascular Pathology Associated With Microangiopathic Hemolytic Anemia Pathology Key Features Examples VWF-platelet thrombosis Fibrin-platelet thrombosis Thrombus with VWF and platelets Endothelium and vessel wall are intact Thrombus with fibrin and platelets Endothelium and vessel wall are intact Thrombotic thrombocytopenic purpura Disseminated intravascular coagulopathy, heparin-induced thrombocytopenia, paroxysmal nocturnal hemoglobinuria, catastrophic antiphospholipid antibody syndrome, HELLP syndrome Microvascular cancer cells Intravascular clusters of cancer cells Metastatic neoplasm Vasculitis Inflammatory cell infiltration Fibrinoid necrosis Fibrous proliferation Disruption of internal elastic lamina Autoimmune diseases, certain infections Thrombotic microangiopathy Endothelial swelling or disruption Subendothelial expansion/cell proliferation Thrombosis present or absent Internal elastic membrane is intact Interstitial edema Cavitary fluid accumulation HELLP hemolysis, elevated liver enzymes and low platelet counts; VWF von Willebrand factor. *Gemcitabine, mitomycin, calcineurin inhibitors, quinine, cocaine, bevacizumab, and others. Atypical hemolytic uremic syndrome, hemolytic uremic syndrome due to shiga toxins or microbial neuraminidases, catastrophic antiphospholipid antibody syndrome, drugs* factor is uniquely capable of supporting platelet adhesion under high shear stress conditions. Because large forms are more responsive to shear stress, this scheme also explains why large von Willebrand factor multimers are hemostatically more effective than small von Willebrand factor multimers. Conformational unfolding and activation of von Willebrand factor by shear stress also occurs in the circulation, Figure 2 Pathology of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. A-D, Microvascular von Willebrand factor thrombosis in a patient who died of thrombotic thrombocytopenic purpura. A, Arteriolar thrombosis in the heart with intact endothelial cells and vessel wall. Immunochemical stain shows von Willebrand factor rich thrombi in the arterioles of the brain (B, C) and kidney (D). von Willebrand factor remains detectable in the endothelial cells. E-H, Thrombotic microangiopathy in the kidney of a patient who died of atypical hemolytic uremic syndrome. E, Endothelial disruption and thrombosis at a juxtaglomerular arteriole. F, A reorganizing arteriolar thrombosis with loss of the endothelial cells. The glomerulus is contracted with thickened subendothelial and mesangial matrix. G, Arteriolar fibrosis and stenosis without thrombosis. H, Marked thickening of the intima, due to matrix expansion and cellular proliferation, causes arteriolar stenosis. The internal elastic lamina is intact (Silver stain).
4 Tsai Untying the Atypical Hemolytic Uremic Syndrome Knot 203 Figure 3 Pathogenesis of microvascular thrombosis in thrombotic thrombocytopenic purpurea. A, At sites of vessel injury, von Willebrand factor binds to the exposed subendothelial collagen and other components, becoming rapidly unfolded and activated by the shear stress at the blood vessel wall boundary. The unfolded von Willebrand factor provides the substrate for platelet adhesion, which is the initial step of normal hemostasis. B, In the circulation, von Willebrand factor is intermittently and partially unfolded by shear stress. ADAMTS13, a plasma metalloprotease, cleaves von Willebrand factor whenever its scissile bonds are exposed. This shear stress-dependent proteolysis maintains the von Willebrand factor in compact, inactive configuration while it becomes progressively smaller multimers. C, Without proteolysis by ADAMTS13, von Willebrand factor is gradually unfolded and activated by shear stress, leading to von Willebrand factor platelet aggregation and intravascular thrombosis characteristic of thrombotic thrombocytopenic purpura. ADAMTS13 a disintegrin and metalloprotease with thrombospondin repeat, member 13; EC endothelial cell; VWF von Willebrand factor. albeit intermittently and gradually. ADAMTS13, a recently discovered plasma metalloprotease, cleaves von Willebrand factor at a scissile bond in the central A2 domain whenever the protein molecule is beginning to undergo shear-induced conformational change. With this process of shear stressdependent proteolysis, von Willebrand factor becomes progressively smaller multimers that maintains their compact, inactive conformations. By this scheme, large von Willebrand factor multimers are available for hemostasis, yet intravascular von Willebrand factor platelet aggregation is prevented. In the absence of adequate ADAMTS13, von Willebrand factor may be gradually activated by shear stress, leading to intravascular von Willebrand factor platelet aggregation and microvascular thrombosis of thrombotic thrombocytopenic purpura (Figure 3). Two causes of severe von Willebrand factor deficiency have been identified: genetic deficiency due to mutations of the ADAMTS13 gene and autoimmune inhibitors of ADAMTS13 activity. 1,2 Clinical observation indicates that platelet consumption does not occur when AD- AMTS13 is greater than 10%. On the other hand, when the ADAMTS13 level is less than 10%, von Willebrand factor platelet thrombosis may but does not invariably occur. This is because the process of von Willebrand factor platelet aggregation is affected by modifiers such as shear stress profile in the microcirculation and other less well understood factors. A variety of pathologic conditions, such as infection, disseminated intravascular coagulopathy, pancreatitis, and pregnancy, may decrease the plasma ADAMTS13
5 204 The American Journal of Medicine, Vol 126, No 3, March 2013 Figure 4 Activation and regulation of the complement system. The complement system is activated by immune complexes via the classic pathway or microbial mannose via the lectin pathway. The alternative pathway includes a loop of amplification that is essential for effective innate defense against infection and is regulated by several plasma and membrane proteins (in red) whose mutations have been detected in patients with atypical hemolytic uremic syndrome. In some patients, autoantibodies of complement factor H or gain-of-function mutations involving complement factor B or C3 (in blue) are detected. CFB complement factor B; CFH complement factor H; CFHR1 complement factor H related protein 1; CFI complement factor I; CFP complement factor P; MASP-1/2 mannan-binding lectin serine protease 1/2; MCP membrane cofactor protein; THBD thrombomodulin. levels. Although the magnitude of decrease in association with these pathologic conditions is inadequate to cause von Willebrand factor platelet aggregation, it may trigger disease presentation in patients with preexisting ADAMTS13 mutations or inhibitors, giving rise to the appearance of secondary thrombotic thrombocytopenic purpura. UNCONTROLLED COMPLEMENT ACTIVATION AND THE ATYPICAL HEMOLYTIC UREMIC SYNDROME The complement activation pathways and their regulators are illustrated in Figure 4. As an integral part of the innate defense mechanism for controlling infection, the complement system encompasses a loop of amplification via the alternative pathway to ensure rapid generation of membrane attack complex (C5b-9) and anaphylatoxins C3a and C5a. The self-perpetuating alternative pathway activation is controlled via several regulators, including complement factor H (CFH), which acts as a cofactor of complement factor I (CFI), a plasma serine protease that cleaves and inactivates C3b. Complement factor H also regulates the other steps generating the alternative pathway C3 and C5 convertases. Membrane cofactor protein (MCP), thrombomodulin (THBD), and complement factor H related proteins 1 to 5 (CFHR1-5) are other proteins that augment the regulation of the alternative pathway activity. Three types of molecular defects have been detected in patients with atypical hemolytic uremic syndrome: inactivating mutations of the regulators (CFH, MCP, CFI, or THBD), gain-of-function mutations of the activators (CFB or C3), and autoantibodies of CFH. Mutations of CFH are the most common, detected in 20% to 25% of patients with atypical hemolytic uremic syndrome. Together, molecular defects are detected in 40% of sporadic and 75% of familial patients with atypical hemolytic uremic syndrome. Combinations of polymorphisms or haplotypes (complotypes) of CFH, CFHR2, and other complement regulators also are associated with higher risks of atypical hemolytic uremic syndrome. 7 Overall, the complexity of its molecular pathogenesis suggests that protein replacement therapy is unlikely to be a viable strategy for the management of atypical hemolytic uremic syndrome.
6 Tsai Untying the Atypical Hemolytic Uremic Syndrome Knot 205 Figure 5 Pathophysiology of atypical hemolytic uremic syndrome. In atypical hemolytic uremic syndrome, uncontrolled complement activation may lead to endothelial injury, resulting in microvascular thrombosis. Endothelial injury also may cause stenosis due to endothelial cell swelling, subendothelial expansion, and reactive cellular proliferation. C3a and C5a may cause abnormal vascular permeability by inducing the release of histamine from basophils and mast cells. Organ dysfunction due to thrombosis is accompanied by thrombocytopenia and microangiopathic hemolysis, but only with microangiopathic hemolysis if it is due to nonthrombotic stenosis and with neither when it is due to interstitial edema. MAC membrane attack complex; RBC red blood cell. PATHOPHYSIOLOGY The clinical manifestation of thrombotic thrombocytopenic purpura results from ischemic injury induced by microvascular thrombosis. As a consequence, the platelet count is generally a reliable indicator of disease activity in thrombotic thrombocytopenic purpura. In contrast, the pathophysiology of atypical hemolytic uremic syndrome is more complex (Figure 5). Endothelial injury induced by C5b-9 (membrane attack complex) may expose the thrombogenic components in the intima to the coagulation proteins and platelets, leading to the development of platelet-fibrin thrombosis. The endothelial injury also may lead to stenosis by causing cellular swelling, subendothelial edema, and reactive cellular proliferation. Furthermore, the C3a and C5a generated during complement activation may induce histamine release from basophils or mast cells, increasing the permeability of the microvasculature. Abnormal vascular permeability may cause interstitial edema and fluid accumulation in cavitary spaces that are common in atypical hemolytic uremic syndrome. Organ dysfunction is associated with thrombocytopenia and microangiopathic hemolysis if it is primarily due to thrombosis; with microangiopathic hemolysis but not thrombocytopenia if it is due to nonthrombotic stenosis; and with neither thrombocytopenia nor microangiopathic hemolysis if it is due to abnormal vascular permeability. Therefore, in atypical hemolytic uremic syndrome, mental status change due to cerebral edema or respiratory distress due to pulmonary edema is not invariably associated with worsening thrombocytopenia or microangiopathic hemolysis. The endothelial injury and stenosis at the glomerular arterioles may cause dysregulation of the juxtaglomerular apparatus, leading to severe but often brittle hypertension without concurrent thrombocytopenia in some patients with atypical hemolytic uremic syndrome. CLINICAL FEATURES The incidence of thrombotic thrombocytopenic purpura is estimated to be 2 to 15 cases/10 6 patient-years. Atypical hemolytic uremic syndrome is likely to be one third to one half as frequent as thrombotic thrombocytopenic purpura, although the diagnosis is often unrecognized (Table 2). Both thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome cause mental status changes. Focal deficits are more common in patients with thrombotic thrombocytopenic purpura but also may occur in atypical hemolytic uremic syndrome. Abdominal symptoms such as pain, nausea, vomiting, and diarrhea are common at acute presentation of atypical hemolytic uremic syndrome but also occur albeit less frequently in thrombotic thrombocytopenic purpura.
7 206 The American Journal of Medicine, Vol 126, No 3, March 2013 Table 2 Comparison of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic-Uremic Syndrome Disorder Thrombotic Thrombocytopenic Purpura Atypical Hemolytic-Uremic Syndrome Molecular defects ADAMTS13 inhibitors ADAMTS13 mutations CFH antibody Genetic defects in C activators or regulators Mode of transmission Acquired Autosomal recessive Acquired Autosomal dominant** Age Teens - adults Children - adults Children - adults Gender (female vs 2-3:1 1:1 1:1 male) Incidence (relative) 1 5% 1/3-1/2 Pathology Microvascular VWF-platelet thrombosis Thrombotic microangiopathy Common presentation Fatigue, headache, dizziness Focal deficits, confusion Petechiae Abdominal pain Fatigue, headache, dizziness Chest pain, dyspnea Abdominal pain, vomiting, diarrhea Somnolence, confusion Thrombocytopenia Generally precedes symptoms and signs May not reflect disease severity Advanced renal failure Rare Occasional Common Hypertension Rare Occasional Common Vascular permeability Cerebral edema, PRES pulmonary edema, effusions, ascites, anasarca Mortality with plasma therapy Rare Rare Common 10% Very low 20%-30% Treatment of choice Plasma exchange Plasma infusion Eculizumab Long-term prognosis* Relapse Stroke Relapse Stroke Renal failure Relapse End-stage renal disease in 30%-40% CFB complement factor B; CFH complement factor H; CFI complement factor I; MCP membrane cofactor protein; PRES posterior reversible encephalopathy syndrome; THBD thrombomodulin; VWF von Willebrand factor. *Without maintenance therapy. **With variable expression. Renal failure and hypertension tend to be severe in patients with atypical hemolytic uremic syndrome, although the serum creatinine level may be only mildly elevated initially, and some patients may not develop severe renal failure or hypertension. Severe renal failure and hypertension are rare with thrombotic thrombocytopenic purpura without comorbid conditions. Complications of abnormal vascular permeability, such as brain or pulmonary edema, pleural or pericardial effusions, ascites and anasarca, occur in approximately one third of patients with atypical hemolytic uremic syndrome but are rare in thrombotic thrombocytopenic purpura without comorbidity. DIFFERENTIAL DIAGNOSIS OF MICROANGIOPATHIC HEMOLYSIS Thrombotic thrombocytopenic purpura is the diagnosis in patients with severe ADAMTS13 deficiency due to autoimmune inhibitors or, less frequently, genetic mutations. The diagnosis of atypical hemolytic uremic syndrome is less straightforward. The diagnosis may be established by demonstrating genetic mutations or complement factor H antibodies. However, the test results are generally not available for weeks to months. Furthermore, negative test results do not exclude the diagnosis of atypical hemolytic uremic syndrome. Atypical hemolytic uremic syndrome is the presumptive diagnosis in patients with renal function impairment not accompanied with severe ADAMTS13 or comorbid conditions, with 2 potential caveats: the uncertain reliability of clinical ADAMTS13 assays and the unapparent nature of some comorbid conditions. Therefore, the diagnosis of atypical hemolytic uremic syndrome should be constantly reevaluated. The diagnosis of atypical hemolytic uremic syndrome is often uncertain in patients with comorbid conditions. The patients without severe ADAMTS13 deficiency may be classified into 5 groups on the basis of the absence or presence of comorbid conditions (Table 3). Group I is primary atypical hemolytic uremic syndrome without comorbid conditions. Group II includes pregnancy and other conditions that are considered to be triggers of exacerbation in patients with atypical hemolytic uremic syndrome. Group III includes conditions that cause defective regulation of the complement system. Some patients develop atypical hemolytic uremic syndrome due to com-
8 Tsai Untying the Atypical Hemolytic Uremic Syndrome Knot 207 Table 3 Classification of Comorbid Conditions in Patients With Microangiopathic Hemolytic Anemia but without Severe ADAMTS13 Group Role Examples I None Idiopathic atypical hemolytic uremic syndrome II Trigger of complement activation Pregnancy, surgery, infection, inflammation, pancreatitis III Acquired complement dysregulation* HIV infection, hematopoietic stem cell therapy, autoimmune diseases (eg, lupus, renal scleroderma, catastrophic antiphospholipid antibody syndrome), drugs IVa Thrombotic microangiopathy via other mechanisms Shiga toxin associated hemolytic uremic syndrome Pneumococcal hemolytic uremic syndrome HIV infection, hematopoietic stem cell therapy, autoimmune diseases (eg, lupus, renal scleroderma, catastrophic antiphospholipid antibody syndrome), drugs Severe hypertension IVb Other types of pathology Fibrin thrombosis Disseminated intravascular coagulopathy, catastrophic antiphospholipid antibody syndrome, hemolysis with elevated liver enzymes and low platelet syndrome of pregnancy, heparin-induced thrombocytopenia, paroxysmal nocturnal hemoglobinuria Microvascular cancer cells Vasculitis, autoimmune or infectious V Unrelated Miscellaneous HIV human immunodeficiency virus. *Except for hematopoietic stem cell therapy, there is no direct evidence as yet that acquired complement dysregulation underlies the thrombotic microangiopathy in patients with HIV infection, autoimmune diseases, or catastrophic antiphospholipid syndrome, or taking drugs (eg, gemcitabine, mitomycin, calcineurin inhibitors, quinine, cocaine, bevacizumab). Severe hypertension may be the manifestation of forme fruste atypical hemolytic uremic syndrome rather than a cause of microangiopathic hemolytic anemia. plement factor H autoantibodies after undergoing hematopoietic stem cell therapy. It is assumed that autoreactive B cells targeting complement factor H may emerge because of defective regulation of autoimmunity after myeloablation. Group IV includes thrombotic microangiopathy due to other mechanisms (IVa) and other types of pathology (IVb). Some comorbid conditions such as autoimmune diseases may cause microangiopathic hemolysis via more than one mechanism (group II, III, or IV). Group V includes comorbid conditions that are unrelated to the development of microangiopathic hemolysis but may complicate the clinical presentation. CLINICAL COURSE AND TREATMENT Acquired thrombotic thrombocytopenic purpura is a chronic autoimmune disorder that is characterized by episodes of exacerbation. During clinical remission with normal platelet count, the patients generally do not develop progressive organ injury. The treatment of acquired thrombotic thrombocytopenic purpura during its exacerbation is plasma exchange to replenish the missing ADAMTS13 and remove the inhibitors. With prompt plasma exchange therapy, approximately 90% of the patients are expected to survive the acute episodes. Plasma therapy does not address the underlying autoimmune nature of acquired thrombotic thrombocytopenic purpura. The patients are responsive to the treatment and able to wean from plasma exchange because the autoimmunity to ADAMTS13 is not intense and spontaneously wanes after a few weeks. In fatal cases, the patients have high levels of ADAMTS13 inhibitors that are not amenable to plasma exchange therapy. 6 Some patients may not be able to wean off plasma exchange therapy because their ADAMTS13 does not recover above the threshold level of suppressing platelet thrombosis. Rituximab has been used, with high rates (70%-90%) of remission, initially in patients unable to wean off plasma exchange even after therapy with corticosteroids, antiplatelet drugs, vincristine, cyclophosphamide, azathioprine, or splenectomy. 8 With its efficacy increasingly appreciated, rituximab is often used before the other modalities. 9 A clinical trial has explored the potential role of preemptive rituximab treatment within a few days of presentation. 10 Compared with historical controls, preemptive rituximab treatment seems to shorten the time to sustained remission and postpone the onset of subsequent relapses. Rituximab suppresses but does not eliminate the ADAMTS13 autoimmunity. Most patients, even those with normalized ADAMTS13 levels spontaneously or after rituximab therapy, are expected to develop relapses during their lifetime. For early detection of impending relapses, periodic complete blood count is inadequate and serial monitoring of the ADAMTS13 level is necessary. The patients may be treated
9 208 The American Journal of Medicine, Vol 126, No 3, March 2013 preemptively with rituximab to prevent relapse if the AD- AMTS13 level is persistently decreased or exhibits a trend of decrease, which often develop over several weeks to months. 6 Patients with hereditary thrombotic thrombocytopenic purpura generally require maintenance plasma infusion therapy every 2 to 3 weeks to prevent exacerbations and progressive renal and other organ injury. Conventionally atypical hemolytic uremic syndrome has been treated as thrombotic thrombocytopenic purpura with plasma exchange, often with unsatisfactory outcomes (Table 2). Maintenance plasma therapy may prevent renal function deterioration in some patients. However, plasma exchange is a technically demanding procedure that is difficult to perform on a long-term basis. Immunosuppressive agents such as rituximab or splenectomy is not expected to be effective for atypical hemolytic uremic syndrome unless it is due to complement factor H autoantibodies. A major advance in the management of atypical hemolytic uremic syndrome is the use of eculizumab, a humanized monoclonal antibody of complement C5 originally approved in 2007 for the treatment of paroxysmal nocturnal hemoglobinuria, another disease due to complement dysregulation. Two prospective clinical trials have demonstrated the efficacy of eculizumab for patients with atypical hemolytic uremic syndrome not responding to plasma exchange or requiring maintenance prophylaxis. 11,12 With eculizumab therapy, renal function improved in the group with active disease and remained stable or slightly improved in the maintenance group. No patients required additional plasma therapy or new dialysis during eculizumab therapy. These trials led to its approval in the United States and European Union for atypical hemolytic uremic syndrome. Eculizumab is generally well tolerated. A major risk is fulminant meningococcal infection. Meningococcal vaccination is mandatory, and the patients should take prophylactic antibiotics at least until 2 weeks after vaccination. Vaccination decreases but does not eliminate the risk of fulminant meningococcal disease. 13 The patients should be well versed on this risk and carry a medication warning card. Long-term prophylactic antibiotics also should be seriously considered. WHO SHOULD BE TREATED WITH ECULIZUMAB AND FOR HOW LONG? Eculizumab is the treatment of choice over plasma exchange for patients with primary atypical hemolytic uremic syndrome, that is, the patients presenting with thrombocytopenia, microangiopathic hemolysis, and renal function impairment but without severe ADAMTS13 deficiency or comorbidity. Eculizumab also should be considered for atypical hemolytic uremic syndrome associated with any of the group II or group III comorbid conditions (Table 3). Patients with end-stage renal disease due to atypical hemolytic uremic syndrome should be treated with eculizumab if they continue to experience extrarenal complications or severe hypertension. For patients with newly diagnosed advanced renal failure, eculizumab treatment may lead to gradual renal function improvement, allowing the discontinuation of dialysis after more than 1 year of treatment. Therefore, patients with advanced renal disease due to atypical hemolytic uremic syndrome should not give up hope of partial recovery or rush prematurely to kidney transplantation. The optimal duration of eculizumab treatment has not been determined. Atypical hemolytic uremic syndrome is a chronic, often progressive disease even in the absence of thrombocytopenia or microangiopathic hemolysis. Therefore, eculizumab probably should be continued indefinitely for patients at the edge of requiring renal replacement therapy and for patients who are likely to have recurrent atypical hemolytic uremic syndrome with serious complications if eculizumab is discontinued. For asymptomatic patients with normal or mildly abnormal renal function, cautious discontinuation of eculizumab may be an option. The patients should be closely monitored for clinical symptoms, blood pressures, blood counts, and renal function. IMPLICATIONS FOR RENAL TRANSPLANTATION Patients with atypical hemolytic uremic syndrome have a high risk of graft failure after kidney transplantation, primarily due to thrombotic microangiopathy affecting the grafts. 14 Unaware of this risk, some patients have received multiple grafts, all ending in failure. Concurrent liver transplantation may prevent thrombotic microangiopathy in the graft by restoring the plasma complement factor H level in patients with CFH mutations. The operation is associated with high rates of perioperative morbidity and mortality unless the patients are pretreated with plasma exchange, most likely due to triggering of the inadequately regulated complement system. Eculizumab therapy, started preoperatively and continued postoperatively, is expected to shift the paradigm. Preliminary experience suggests that with eculizumab therapy excessive morbidity, mortality, and kidney graft failure may be prevented and liver transplantation is not essential Some of the patients with atypical hemolytic uremic syndrome may present with advanced renal disease without history or evidence of microangiopathic hemolysis and thrombocytopenia. Consequently, kidney biopsy or molecular tests for atypical hemolytic uremic syndrome are recommended for patients with renal failure of undetermined causes if kidney transplantation is being considered. Family members of patients with atypical hemolytic uremic syndrome may have the same genetic defects but are asymptomatic. They should refrain from donating their organs.
10 Tsai Untying the Atypical Hemolytic Uremic Syndrome Knot 209 CONCLUSIONS The last 15 years have witnessed exciting breakthroughs in understanding the causes of microangiopathic hemolysis: the discovery of ADAMTS13 and its deficiency in thrombotic thrombocytopenic purpura and the discovery of defective complement regulation in atypical hemolytic uremic syndrome. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome are distinct disorders that happen to share the common feature of thrombocytopenia and microangiopathic hemolysis because they both cause arteriolar thrombosis, albeit via completely different mechanisms. The autoimmune nature of acquired thrombotic thrombocytopenic purpura has prompted the use of rituximab to induce remission in patients with persistent disease activity and to prevent its relapse. The development of recombinant ADAMTS13 proteins may make plasma exchange treatment obsolete in the future. Eculizumab prevents death and end-stage renal disease and facilitates renal function recovery in patients with atypical hemolytic uremic syndrome. Many cases of atypical hemolytic uremic syndrome are not recognized or continue to be treated as thrombotic thrombocytopenic purpura. With eculizumab available as an effective treatment, it is imperative to recognize atypical hemolytic uremic syndrome as a distinct disorder that requires its own strategy of management. References 1. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339: Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413: Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 2010;31:E1445- E Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial ahus and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5: Malina M, Roumenina LT, Seeman T, et al. Genetics of hemolytic uremic syndromes. Presse Med. 2012;41(3 Pt 2):e105-e Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost. 2012;38: Ermini L, Goodship TH, Strain L, et al. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with ahus. Mol Immunol. 2012;49: Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28: Elliott MA, Heit JA, Pruthi RK, Gastineau DA, Winters JL, Hook CC. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol. 2009;83: Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118: Loirat C, Babu S, Furman R, et al. Eculizumab efficacy and safety inpatients with atypical hemolyticuremic syndrome (ahus) resistant to plasma exchange/infusion. Haematologica. 2011;96:S Loirat C, Muus P, Legendre C, et al. A phase II study of eculizumab in patients with atypical hemolyticuremic syndrome receiving chronic plasma exchange/infusion. Haematologica. 2011;96:S Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117: Zuber J, Le QM, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7: Krid S, Roumenina L, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant. 2012;12: Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2011;6: Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26:
New insights in thrombotic microangiopathies : TTP and ahus
New insights in thrombotic microangiopathies : TTP and ahus Dr Catherine LAMBERT Hematology Cliniques universitaires Saint-Luc Catherine.lambert@uclouvain.be New insights in thrombotic microangiopathies
More informationAtypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature
Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature Mouhanna Abu Ghanimeh 1, Omar Abughanimeh 1, Ayman Qasrawi 1, Abdulraheem
More informationM.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve.
M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationHemolytic uremic syndrome: Investigations and management
Hemolytic uremic syndrome: Investigations and management SAWAI Toshihiro M.D., Ph.D. Department of Pediatrics, Shiga University of Medical Science Otsu, JAPAN AGENDA TMA; Thrombotic micro angiopathy STEC-HUS;
More informationClinical Study Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome
Hindawi Publishing Corporation Advances in Hematology Volume 214, Article ID 295323, 7 pages http://dx.doi.org/1.1155/214/295323 Clinical Study Therapy Leads to Rapid Resolution of Thrombocytopenia in
More informationThrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13
Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13 Mark Cunningham,MD Director, Hematology Laboratory Department of Pathology University of Kansas Medical Center College of American Pathologists
More informationDRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)
Preamble: A confirmed diagnosis of atypical hemolytic uremic syndrome (ahus) is required for eculizumab funding. The information below is to provide clinicians with context for how a diagnosis of ahus
More informationTMA in HUS and TTP: new insights
TMA in HUS and TTP: new insights Daan Dierickx University Hospitals Leuven, Department of Hematology, Belgium 20th Annual Meeting Belgian Society on Thrombosis and Haemostatis Antwerpen, 22 th November
More informationAccepted Manuscript. No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please. Yeong-Hau H. Lien MD, PhD S (18)
Accepted Manuscript No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please Yeong-Hau H. Lien MD, PhD PII: S0002-9343(18)30965-3 DOI: https://doi.org/10.1016/j.amjmed.2018.10.009 Reference:
More informationR. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk
R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy Lindsay Keir Richard
More informationTHROMBOTIC MICROANGIOPATHY. Jun-Ki Park 7/19/11
THROMBOTIC MICROANGIOPATHY Jun-Ki Park 7/19/11 TMAs are microvascular occlusive disorders characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes.
More informationWhat is meant by Thrombotic Microangiopathy (TMA)?
What is meant by Thrombotic Microangiopathy (TMA)? Thrombotic Microangiopathy (TMA) is a group of disorders characterized by injured endothelial cells, microangiopathic hemolytic anemia (MAHA), with its
More informationSoliris (eculizumab) DRUG.00050
Market DC Soliris (eculizumab) DRUG.00050 Override(s) Prior Authorization Approval Duration 1 year Medications Soliris (eculizumab) APPROVAL CRITERIA Paroxysmal Nocturnal Hemoglobinuria I. Initiation of
More informationTMA CASE STUDY. Pamela Harmon, RN & Keturah Tomlin, RN Toronto General Hospital Apheresis Unit
TMA CASE STUDY Pamela Harmon, RN & Keturah Tomlin, RN Toronto General Hospital Apheresis Unit Cumulative fraction of patients free of events ahus is a catastrophic disease that can result in sudden & progressive
More informationSafety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SA-PO546 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid,
More informationThrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular. Genetics
Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular Genetics Helen Liapis, M.D. Senior Consultant Arkana Labs Professor of Pathology & Immunology. retired Washington University School
More informationSafety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SP281 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid, 3 Chantal
More informationRecent advances in pathogenesis & treatment of ahus
Recent advances in pathogenesis & treatment of ahus Miquel Blasco Pelicano Nephrology and Kidney Transplant Unit Hospital Clínic, Barcelona Atypical Hemolytic Uremic Syndrome (ahus) Ultra-rare disease:
More information* Renal insufficiencies
Thrombotic Thrombocytopenic Purpura Behzad Poopak, DCLS PhD. Tehran medical Branch Islamic Azad university bpoopak@yahoo.com Case Summary Ms. X, a 35-year year-old woman Complained of weakness, low grade
More informationahus A PATIENT S GUIDE To learn more about ahus, visit Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved.
To learn more about ahus, visit www.ahussource.com ahus A PATIENT S GUIDE Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved. SOL 1169 BECOME EMPOWERED By learning more and taking control
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationDR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL
DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL Rare but fatal disease if unrecognized and untreated Incidence about 1: 1 million in the USA Female preponderance of 2:1 Part
More informationHemolytic uremic syndrome
Hemolytic uremic syndrome Doyeun Oh Department of Internal Medicine CHA University School of Medicine Disclosures for Doyeun Oh Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau
More informationThrombotic thrombocytopenic purpura: a look at the future
Thrombotic thrombocytopenic purpura: a look at the future Andrea Artoni, MD Ph.D. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca Granda Ospedale Maggiore Policlinico Milan, Italy andrea.artoni@policlinico.mi.it
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More informationHUS and TTP Testing. Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI
HUS and TTP Testing Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI Disclosures Relevant Financial Relationships Consultant: Ablynx, Bayer, CSL Behring,
More informationSome renal vascular disorders
Some renal vascular disorders Introduction Nearly all diseases of the kidney involve the renal blood vessels secondarily We will discuss: -Hypertension (arterionephrosclerosis in benign HTN & hyperplastic
More informationTHE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES
THE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES Summary of Presentations from the Alexion-Sponsored Symposium, held at the 19 th EHA Congress, Milan, Italy, on 12 th June 2014 Chairperson Pier Mannuccio
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Soliris (eculizumab) Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Soliris (eculizumab) Prime Therapeutics will review Prior Authorization requests
More informationRisk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy
Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris WWA SFH
More informationLet`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016
Let`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016 Case report 20 months old girl Israeli Arab Muslim family, consanguineous marriage
More informationSpectrum of complement-mediated thrombotic microangiopathies after kidney transplantation
Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation Marius Miglinas Vilnius university hospital: Nephrology center, Center of Rare Kidney Diseases Vilnius university
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: eculizumab_soliris 8/2014 4/2018 4/2019 4/2018 Description of Procedure or Service Paroxysmal nocturnal hemoglobinuria
More informationEculizumab as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Adult Living-Related Kidney Transplantation
Anti-C5 as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Living- Related Kidney Transplantation Authors: Miquel Blasco 1, Santiago Rodríguez de Córdoba 2, Fritz Diekmann 1, Mercedes Saiz
More informationLAMA SHATAT TTP, ITP, DIC
TTP, ITP, DIC Reduction in platelet number (thrombocytopenia) constitutes an important cause of generalized bleeding. A count less than 100,000 platelets/μl is generally considered to constitute thrombocytopenia.
More informationInitial management of TMA syndromes
Initial management of TMA syndromes Elie Azoulay, Saint-Louis Hospital, Medical Intensive Care Unit Paris Diderot Sorbonne University Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique
More informationSoliris and You. Your Guide To Living With ahus. INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab)
INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab) INDICATION What is SOLIRIS? SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat: adults and children
More informationThrombotic Microangiopathy (TMA) The Clinical Facets of TMA
International Consensus on Management Atypical Hemolytic Uremic Syndrome in Children Loirat C. et al. Pediatr Nephrol 31: 15-39, 2016 Ruth A. McDonald, MD Professor and Vice Chair Clinical Affairs Department
More informationMost Common Hemostasis Consults: Thrombocytopenia
Most Common Hemostasis Consults: Thrombocytopenia Cindy Neunert, MS MSCS Assistant Professor, Pediatrics CUMC Columbia University TSHNA Meeting, April 15, 2016 Financial Disclosures No relevant financial
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, et al. Eculizumab
More informationNot So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor
More informationMedical Policy. MP Eculizumab (Soliris) Related Policies None. Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug
Medical Policy Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug Related Policies None DISCLAIMER Our medical policies are designed for informational purposes only and are not
More informationSoliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus)
Soliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus) New Data from the Largest Prospective Trial of Adult Patients
More informationBleeding and Thrombotic Disorders. Kristine Krafts, M.D.
Bleeding and Thrombotic Disorders Kristine Krafts, M.D. Bleeding and Thrombotic Disorders Bleeding disorders von Willebrand disease Hemophilia A and B DIC TTP/HUS ITP Thrombotic disorders Factor V Leiden
More informationA 60 year old woman with altered mental status and thrombotic microangiopathy. Josh Veatch
A 60 year old woman with altered mental status and thrombotic microangiopathy Josh Veatch Previously healthy 60 year old woman 2 3 months of fatigue following a URI, transient episodes being out of it
More informationDr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL
Dr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL CASE HISTORY 4 yrs old previously well boy Born to 2 nd degree consanguinity Fever x 5 days
More informationThrombotic Thrombocytopenic
The Treatment of TTP and the Prevention of Relapses GERALD APPEL, MD Professor of Clinical Medicine Columbia University College of Physicians and Surgeons NY-Presbyterian Hospital New York, New York Thrombotic
More informationSpecialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus)
Specialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus) Document Author: Assistant Director for Evidence, Evaluation and Effectiveness Executive Lead: Medical Director
More informationC3 Glomerulopathy. Jun-Ki Park
C3 Glomerulopathy Jun-Ki Park 03.08.11 For the last 30 years classification MPGN is based on glomerular findings by light microscopy with further specification on EM and staining for Ig and complement
More informationM1 - Immunology, Winter 2008
University of Michigan Deep Blue deepblue.lib.umich.edu 2008-09 M1 - Immunology, Winter 2008 Fantone, J.; Pietropaolo, M. T. Fantone, J., Pietropaolo, M. T. (2008, August 13). Immunology. Retrieved from
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Barry Skikne MD, FACP, FCP(SA) Professor of Hematology Division of Hematologic Malignancies and Cellular Therapeutics Cardinal Clinical Manifestations PNH Clonal disease
More informationSchematic Of Heparin Induced Thrombocytopenia Platelet Count
Schematic Of Heparin Induced Thrombocytopenia Platelet Count Normal IgG and IgG2 differentially inhibit HIT antibody-dependent platelet activation that platelet counts were lower in FcγRIIA 131RR patients
More informationYear 2004 Paper one: Questions supplied by Megan
QUESTION 53 Endothelial cell pathology on renal biopsy is most characteristic of which one of the following diagnoses? A. Pre-eclampsia B. Haemolytic uraemic syndrome C. Lupus nephritis D. Immunoglobulin
More informationChallenges in Renal Apheresis. Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School
Challenges in Renal Apheresis Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School Outline Principles of Separation ASFA Guidelines Renal
More informationPNH ahus. Dosing and Administration. For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients
For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients PNH ahus Dosing and Administration Soliris is indicated for the treatment of patients with paroxysmal
More informationWhen a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus?
When a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus? ADAMTS13 activity >5% RULES OUT a diagnosis of severe ADAMTS13 deficiency (TTP)
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More informationApproccio morfologico alle microangiopatie trombotiche
Approccio morfologico alle microangiopatie trombotiche Gina Zini Polo Oncologia e Ematologia Policlinico A. Gemelli Università Cattolica S. Cuore - Roma 1 Thrombotic microangiopathies Occlusive microangiopathic
More informationIntroduction to pathogenesis and treatment of thrombotic microangiopathies (TMA)
Introduction to pathogenesis and treatment of thrombotic microangiopathies (TMA) JM.Campistol, Nephrology and Renal Transplant Department, Hospital Clinic, University of Barcelona, Barcelona, Spain. jmcampis@clinic.cat
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:
More informationA Rational Approach to Evaluation of Thrombotic Microangiopathy
A Rational Approach to Evaluation of Thrombotic Microangiopathy An Algorithmic Approach C. Christopher Hook, MD for the Complement Alternative Pathway Thrombotic Micro- Angiopathy (CAP-TMA) Disease-Oriented
More informationPNH ahus gmg. Dosing and Administration Guide
Injection for Intravenous Use PNH ahus gmg For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus), and generalized Myasthenia Gravis (gmg) patients Dosing and Administration
More informationPathology note 8 BLEEDING DISORDER
Pathology note 8 BLEEDING DISORDER Slide75 ( Types of clotting factors deficiency): Today we will talk about public public factor deficiency it could be acquired or inherited, acquired diseases are more
More informationA 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis).
A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis). He was found to have severe kidney injury requiring
More informationSacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam
Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research,
More informationThrombotic microangiopathy and indications for therapeutic plasma exchange
SPIN DOCTORS:APHERESIS FOR HEMATOLOGISTS Thrombotic microangiopathy and indications for therapeutic plasma exchange Jill Adamski 1 1 Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona,
More informationC3 Glomerulonephritis versus C3 Glomerulopathies?
Washington University School of Medicine Digital Commons@Becker Kidneycentric Kidneycentric 2016 C3 Glomerulonephritis versus C3 Glomerulopathies? T. Keefe Davis Washington University School of Medicine
More informationNon-immune acquired haemolytic anaemias. Dr.Maysem
Non-immune acquired haemolytic anaemias Dr.Maysem Causes of Non-immune acquired haemolytic anaemias. Infections Infections can cause haemolysis in a variety of ways: -They may precipitate an acute haemolytic
More informationThrombotic thrombocytopenic purpura: 2008 Update
MEDICAL GRAND ROUNDS CME CREDIT MARK A. CROWTHER, MD Director, Division of Hematology, McMaster University, Hamilton, Ontario, Canada JAMES N. GEORGE, MD Hematology-Oncology Section, Department of Medicine,
More informationSoliris Medical Policy Prior Authorization Program Summary
Soliris Medical Policy Prior Authorization Program Summary Precertification/Prior Authorization may be required under certain plans. Please verify each member s benefits. OBJECTIVE The intent of the Soliris
More informationInflammation. (4 of 5)
Inflammation (4 of 5) What will we discuss today? Plasma protein derived mediators Anti-inflammatory mediators Morphologic patterns of acute inflammation Plasma protein derived mediators 3 systems: -Complement
More informationDiagnosis and Treatment of Common TMAs
Diagnosis and Treatment of Common TMAs K. Pavenski, MD FRCPC St. Michael s Hospital June 13, 2014 Disclosures I have a relevant conflict of interest - Alexion Pharmaceuticals Inc. Participated in advisory
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug
More informationLiving with PNH 7/3/2013. Paroxysmal Nocturnal Hemoglobinuria (PNH): A Chronic, Systemic, and Life- Threatening Disease
Living with PNH Laurence A. Boxer, MD University of Michigan Case Study 15 year old awakened in the morning with chest pain and a sore throat. She experienced chest pain all day accompanied with coughing
More informationComplement pathways: Classical pathway Alternative pathway Lectin pathway
Complement Complement pathways: Classical pathway Alternative pathway Lectin pathway Complement proteins Classical pathway C1q C1r C1s C4 C2 Alternative pathway D C3 B Lectin pathway MBL MASP-1 MASP-2
More information1) unexplained microangiopathic hemolytic anemia (Coombs negative anemia),
Ravi Sarode, MD Consensus Process The TTP-CC subcommittee developed 7 key questions Sent to the 7 speakers for electronic voting in Yes or No format Will be published in JCA soon Q.1 Untreated TTP carries
More information3/31/2014 PNH. Jack Goldberg MD FACP. Clinical Professor of Medicine University of Pennsylvania
PNH Jack Goldberg MD FACP Clinical Professor of Medicine University of Pennsylvania 1 2 3 4 1 5 6 Historically Viewed as a Hemolytic Anemia Normal red blood cells are protected from complement attack by
More informationPRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER
PRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER BEFORE STARTING YOUR PATIENTS ON SOLIRIS Important safety information for the healthcare provider Prior to initiating
More informationw ahus pathology is linked to dysregulation of the alternative complement pathway.
ahus - Pathogenesis, Etiology, and Clinical Advances Craig B. Langman MD The Isaac A Abt MD Professor of Kidney Diseases Feinberg School of Medicine, Northwestern University Head, Kidney Diseases The Ann
More information3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:
More informationPATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS. Before starting on Soliris Important safety information for patients
PATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS Before starting on Soliris Important safety information for patients Before you begin Soliris (eculizumab) treatment, your physician will
More informationCoding... 5 Benefit Application... 5 Description of Services... 6 Clinical Evidence... 7
TABLE OF CONTENTS Product Variations.... 1 Policy Statement.... 1 Related Policies.... 4 Policy Guidelines..... 4 Coding.... 5 Benefit Application........ 5 Description of Services..... 6 Clinical Evidence.......
More informationSara K. Vesely, James N. George, Bernhard Lämmle, Jan-Dirk Studt, Lorenzo Alberio, Mayez A. El-Harake, and Gary E. Raskob
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS ADAMTS13 activity in thrombotic thrombocytopenic purpura hemolytic uremic syndrome: relation to presenting features and clinical outcomes in
More informationHEMODYNAMIC DISORDERS
HEMODYNAMIC DISORDERS Normal fluid homeostasis requires vessel wall integrity as well as maintenance of intravascular pressure and osmolarity within certain physiologic ranges. Increases in vascular volume
More informationRenal failure and thrombocytopaenia? Don t forget TTP/HUS. Jonathan Wala Nephrologist
Renal failure and thrombocytopaenia? Don t forget TTP/HUS Jonathan Wala Nephrologist Thrombotic microangiopathies Disorders characterized by: thrombocytopaenia microangiopathic haemolytic anaemia (MAHA)
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute lung injury (ALI) transfusion-related, 363 372. See also Transfusion-related acute lung injury (TRALI) ALI. See Acute lung injury
More informationA 36 year old previously healthy female develops fever and ruising
Renal vascular diseases CPC G.A. Appel MD M.B. Stokes MD Case 1 A 36 year old previously healthy female develops fever and bruising. She goes to her LMD and CBC shows plats 15 K, Hct 28%, normal PT and
More informationHemolytic Uremic Syndrome
Hemolytic Uremic Syndrome Francesco Emma Division of Nephrology and Dialysis Bambino Gesù Children s Hospital, IRCCS Rome, Italy Hemolytic Uremic Syndrome (HUS) microangiopathic hemolytic anemia thrombocytopenia
More informationTTP, Sickle Cell Disease, and the role of von Willebrand factor
TTP, Sickle Cell Disease, and the role of von Willebrand factor José A. López Puget Sound Blood Center University of Washington Seattle, WA Disclosures No conflicts to disclose. Thrombotic Thrombocytopenic
More informationPathophysiology 7/18/2012 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA OUTLINE OF DISCUSSION WHAT IS IT WHO GETS IT NATURAL HISTORY TYPES RISKS COURSE TREATMENTS SYMPTOMS PREGNANCY Pathophysiology Acquired hematopoietic stem cell disorder
More informationBefore starting on Soliris.
Before starting on Soliris. Important safety information for patients Before you begin Soliris (eculizumab) treatment, your physician will give you a: Medication Guide Soliris Patient Safety Information
More informationHematologic Disorders. Assistant professor of anesthesia
Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's
More informationHaemolytic uraemic syndrome the story of a whodunit
Haemolytic uraemic syndrome the story of a whodunit Paul Warwicker Lancashire Teaching Hospitals NHS Trust RCP Kidney for the General Physician Conference Nov 17 Renal thrombotic microangiopathy (TMA)
More informationPresentation Outline. Disease Background Previous research on platelet recovery rate Goal of our study Methods Results Limitations Conclusions
Platelet Recovery Rate at Day 5 of Therapeutic Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura Can Aid in Identifying Risk of Disease Exacerbation Suzanne Zhou, Yara A. Park, Marian A.
More informationIntroduction. Arif Asif 1 Ali Nayer 2 Christian S. Haas 3
J Nephrol (2017) 30:347 362 DOI 10.1007/s40620-016-0357-7 REVIEW Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment
More informationThrombotic Microangiopathies
Thrombotic Microangiopathies ASH/San Antonio Breast Cancer Symposium Review James N. George March 14, 2015 Thrombotic Microangiopathies (TMA): Everything you need to know from 5 patient stories Thrombotic
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant
More informationUnderstanding of the pathophysiology
CMAJ Early release, published at www.cmaj.ca on October 17, 2016. Subject to revision. Review CME Thrombotic microangiopathies: a general approach to diagnosis and management Donald M. Arnold MD MSc, Christopher
More informationPlatelet Disorders. By : Saja Al-Oran
Platelet Disorders By : Saja Al-Oran Introduction The platelet arise from the fragmentation of the cytoplasm of megakaryocyte in the bone marrow. circulate in the blood as disc-shaped anucleate particles
More information